Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/20/2024 | Overweight | Cantor Fitzgerald | |
| 8/13/2024 | $18.00 → $22.00 | Outperform → Strong Buy | Raymond James |
| 8/12/2024 | $19.00 → $20.00 | Outperform | Leerink Partners |
| 7/25/2024 | $18.00 | Outperform | Raymond James |
| 3/5/2024 | $6.00 → $18.00 | Market Perform → Outperform | Leerink Partners |
| 2/20/2024 | Mkt Perform → Outperform | William Blair | |
| 9/20/2023 | Outperform → Mkt Perform | William Blair | |
| 1/31/2023 | $10.00 | Outperform | Wedbush |
Agreement leverages ALK's global footprint in developing and commercializing innovative allergy products ARS Pharma to receive an upfront cash payment of $145 million, with total deal consideration of up to $465 million plus double-digit royalties on net sales ARS Pharma retains all U.S. rights, and existing partnerships in Japan, China, Australia and New Zealand with Alfresa, Pediatrix and CSL, respectively SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced a licens
ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (("ARS Pharma", NASDAQ:SPRY). The agreement grants ALK exclusive global rights to the neffy® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal delivers on key elements in ALK's new strategy Allergy+ and supports ALK's long-term financial ambitions. Needle-free, nasal delivery of adrenaline has the potential to become an important treatment option in anaphylaxisALK also gains rights to future indications, including acute urticaria flares (in development)ALK to pay USD 145 million in up
SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today that seven abstracts will be featured tomorrow, Friday, October 25 at the 2024 ACAAI Annual Scientific Meeting taking place in Boston, Massachusetts. The posters highlight a wide range of studies focused on intranasal epinephrine administration, including cardiovascular safety, human factor study of carrying two devices at all times, and real-world administration data in pediatric patients. "The research being p
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)
SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
SC 13D/A - ARS Pharmaceuticals, Inc. (0001671858) (Subject)
ALK (ALKB:DC / OMX: ALK B) today announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (("ARS Pharma", NASDAQ:SPRY). The agreement grants ALK exclusive global rights to the neffy® adrenaline (epinephrine) nasal spray, with exception of the USA, Australia, New Zealand, Japan and China. The deal delivers on key elements in ALK's new strategy Allergy+ and supports ALK's long-term financial ambitions. Needle-free, nasal delivery of adrenaline has the potential to become an important treatment option in anaphylaxisALK also gains rights to future indications, including acute urticaria flares (in development)ALK to pay USD 145 million in up
neffy Offers Adults and Children (≥30 kg) Living with Severe Allergic Reactions the First New Delivery Method for Epinephrine in more than 35 Years Well-capitalized to Support Launch and Commercialization of neffy in the U.S., and an Expected Operating Runway of at Least Three Years ARS Pharma to Host Investor Conference Call on Monday, August 12, 2024, at 8:00 am ET SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced that the U.S. Food and Drug Administration (FDA)
The CHMP recommended related market authorization in the European Union (EU) for the emergency treatment of allergic reactions (anaphylaxis). The CHMP positive opinion will now be submitted to the European Commission (EC) for the formal marketing authorization process, which is expected to occur in Q3 2024.
ARS Pharmaceuticals (NASDAQ:SPRY) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate.
CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat dose PK/PD study of neffy under NAC conditions and updated testing concerning nitrosamine levelsExclusive licensing deal for Australia and New Zealand with CSL Seqirus; CSL Seqirus will be responsible for applying for regulatory approval, reimbursement and commercialization of neffy. ARS Pharmaceuticals will be responsible for manufacturing and product supply.SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to development o
Cantor Fitzgerald initiated coverage of ARS Pharmaceuticals with a rating of Overweight
Raymond James upgraded ARS Pharmaceuticals from Outperform to Strong Buy and set a new price target of $22.00 from $18.00 previously
Leerink Partners reiterated coverage of ARS Pharmaceuticals with a rating of Outperform and set a new price target of $20.00 from $19.00 previously
10-Q - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
8-K - ARS Pharmaceuticals, Inc. (0001671858) (Filer)
4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)